Paper41454405
Long non-coding RNAs in the tumor immune microenvironment of non-small cell lung cancer: mechanisms and clinical translational perspectives.
Wang W and 6 others. J Transl Med, 2025. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Long non-coding RNAs in the tumor immune microenvironment of non-small cell lung cancer: mechanisms and clinical translational perspectives. Papers, record 41454405. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41454405
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Long non-coding RNAs in the tumor immune microenvironment of non-small cell lung cancer: mechanisms and clinical translational perspectives.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| RNA, Long Noncoding | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Tumor Microenvironment | Major topic |
| Lung Neoplasms | Major topic |
| Translational Research, Biomedical | Major topic |
| Humans | |
| Animals | |
| Immunotherapy |
Source PubMed
References88
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32259264 | Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer. | JAMA Netw Open | 2020 | https://conductscience.org/library/papers/32259264 | PubMed |
| 2 | 36706831 | Shiny transcriptional junk: lncRNA-derived peptides in cancers and immune responses. | Life Sci | 2023 | https://conductscience.org/library/papers/36706831 | PubMed |
| 3 | 8970741 | RGD and other recognition sequences for integrins. | Annu Rev Cell Dev Biol | 1996 | https://conductscience.org/library/papers/8970741 | PubMed |
| 4 | 37909877 | Screening for lung cancer: 2023 guideline update from the American Cancer Society. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/37909877 | PubMed |
| 5 | 35658874 | Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis. | Cell Mol Biol Lett | 2022 | https://conductscience.org/library/papers/35658874 | PubMed |
| 6 | 33434533 | FAM207BP, a pseudogene-derived lncRNA, facilitates proliferation, migration and invasion of lung adenocarcinoma cells and acts as an immune-related prognostic factor. | Life Sci | 2021 | https://conductscience.org/library/papers/33434533 | PubMed |
| 7 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 8 | 37146936 | Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer. | Cancer Lett | 2023 | https://conductscience.org/library/papers/37146936 | PubMed |
| 9 | 33674747 | LY6K-AS lncRNA is a lung adenocarcinoma prognostic biomarker and regulator of mitotic progression. | Oncogene | 2021 | https://conductscience.org/library/papers/33674747 | PubMed |
| 10 | 38484655 | A comprehensive review of lncRNA CRNDE in cancer progression and pathology, with a specific glance at the epithelial-mesenchymal transition (EMT) process. | Pathol Res Pract | 2024 | https://conductscience.org/library/papers/38484655 | PubMed |
| 11 | 37142269 | m6A-mediated upregulation of lncRNA-AC026356.1 promotes cancer stem cell maintenance in lung adenocarcinoma via activating Wnt signaling pathway. | Aging (Albany NY) | 2023 | https://conductscience.org/library/papers/37142269 | PubMed |
| 12 | 35415876 | LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non-small cell lung cancer. | Clin Transl Med | 2022 | https://conductscience.org/library/papers/35415876 | PubMed |
| 13 | 38574881 | LncRNA RGMB-AS1 inhibits HMOX1 ubiquitination and NAA10 activation to induce ferroptosis in non-small cell lung cancer. | Cancer Lett | 2024 | https://conductscience.org/library/papers/38574881 | PubMed |
| 14 | 35117761 | LncRNA FENDRR-mediated tumor suppression and tumor-immune microenvironment changes in non-small cell lung cancer. | Transl Cancer Res | 2020 | https://conductscience.org/library/papers/35117761 | PubMed |
| 15 | 33849634 | PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity. | Genome Biol | 2021 | https://conductscience.org/library/papers/33849634 | PubMed |
| 16 | 36360316 | Radiosensitization-Related Cuproptosis LncRNA Signature in Non-Small Cell Lung Cancer. | Genes (Basel) | 2022 | https://conductscience.org/library/papers/36360316 | PubMed |
| 17 | 35896612 | Evaluating the utility of an immune checkpoint-related lncRNA signature for identifying the prognosis and immunotherapy response of lung adenocarcinoma. | Sci Rep | 2022 | https://conductscience.org/library/papers/35896612 | PubMed |
| 18 | 36147664 | Computational solutions for spatial transcriptomics. | Comput Struct Biotechnol J | 2022 | https://conductscience.org/library/papers/36147664 | PubMed |
| 19 | 26433395 | Statistical controversies in clinical research: long-term follow-up of clinical trials in cancer. | Ann Oncol | 2015 | https://conductscience.org/library/papers/26433395 | PubMed |
| 20 | 37380368 | PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis. | J Immunother Cancer | 2023 | https://conductscience.org/library/papers/37380368 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42582172 | Evolving non-invasive biomarkers in NSCLC immunotherapy: integrating liquid biopsy and multi-omics profiling for precision oncology. | Front Immunol | 2026 | https://conductscience.org/library/papers/42582172 | PubMed |
| 42500647 | Long non-coding RNAs and their potential role in predicting immunotherapy response and prognosis: a systematic review. | Front Immunol | 2026 | https://conductscience.org/library/papers/42500647 | PubMed |
| 42292412 | Tumor-immune crosstalk in lung cancer: emerging roles of long non-coding RNAs. | Front Immunol | 2026 | https://conductscience.org/library/papers/42292412 | PubMed |
| 42199421 | Negative regulators antagonizing antitumor innate immune pathways in lung cancer immune evasion. | Front Immunol | 2026 | https://conductscience.org/library/papers/42199421 | PubMed |
| 42180976 | Ferroptosis-related lncRNA signature predicts prognosis and treatment response in colon cancer. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42180976 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41454405
GET https://conductscience.org/api/papers/v1/41454405/references?page=2